Идёт набор NCT06846710

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Фаза I С лечением Psoriasis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: HS-20118, HS-20118 placebo.
Кому может быть актуально: Состояния в реестре: Psoriasis. Базовые параметры: 18 лет — 65 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Новая Зеландия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of HS-20118 in Adult Participants

Обзор

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .

Подробное описание

Part 1 will consist of 5 cohorts, i.e., X1 mg, X2 mg, X3 mg, X4 mg, and X5 mg dose cohorts (each cohort will include 3 participants to receive placebo). There will be no restriction on the male-to-female ratio. Each cohort will include 12 participants (HS-20118:placebo = 9:3), with a total of 60 participants. Participants will undergo PK blood sampling, ADA blood sampling, PD blood sampling and safety examinations during the study.

Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis.

Part 2 will tentatively consist of 6 cohorts ( HS-20118 vs placebo = 9:3), i.e., (1) A1 mg, (2) A2 mg, (3) A3 mg, (4) A4 mg, (5) A5 mg, (6) A6 mg. Each cohort will include 12 participants (HS-20118:placebo = 9:3), with a total of 72 participants. There will be no restriction on the male-to-female ratio. Participants will undergo PK blood sampling, ADA blood sampling, PD blood sampling and safety examinations during the study.

Вмешательства

Препарат HS-20118
Single and multiple ascending doses of HS-20118 orally
Другое HS-20118 placebo
Single and multiple ascending doses of HS-20118-matched placebo orally

Первичные конечные точки

Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Number of participants with abnormalities of physical examination [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Number of participants with abnormalities of vital signs [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Number of participants with clinical laboratory abnormalities [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Number of participants with abnormalities of electrocardiogram (ECG) parameters [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]

Вторичные конечные точки (12)

Cmax [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Tmax [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
AUC [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
t½ [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
CL/F [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Vd/F [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Rac [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Incidence of Anti-drug antibody (ADA) [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Proportions of psoriasis area and severity index (PASI) 75 [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Proportions of psoriasis area and severity index (PASI) 90 [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Proportions of psoriasis area and severity index (PASI) 100 [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]
Proportions of Investigator's Global Assessment (IGA) 0/1 [Срок оценки: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)]

Критерии участия

Критерии включения

For the SAD study:

Healthy adults aged 18-45 years (inclusive) at the time of signing the informed consent form;
Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg; body mass index (weight/square of height (kg/m2)) within the range of 18-28 kg/m2 (inclusive);
Normal results or abnormal results but without clinical significance in comprehensive examinations, including general physical examination, vital signs, laboratory tests, 12-lead ECG, abdominal color Doppler ultrasound, and chest X-ray from the frontal and lateral position ;

For the MAD study:

Male or female participants aged 18-65 years (inclusive) at the time of signing the informed consent form;
Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg;
Chronic plaque psoriasis for at least 6 months with or without psoriatic arthritis;

Критерии исключения

For the SAD study:

Participants with immune-related diseases and medical history at screening;
Participants with a history of drug or other allergies who are considered by the investigator to be at high risk for participating in this study, or who may be allergic to the investigational medicinal product or any component of the investigational medicinal product as judged by the investigator;
History of drug abuse within the past 5 years or use of illicit drugs within 3 months before the study; or positive for urine drug screening;

For the MAD study:

Guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced psoriasis, or other diseases that affect the treatment results;
Current use of illicit drugs or prior use of illicit drugs within the specific time periods;
Known history of recurrent or chronic infections, or prior history of chronic or recurrent infections, including but not limited to: chronic renal infection, chronic chest infection (e.g., bronchiectasis), symptomatic urinary tract infection, and open, draining, or infected skin wounds; history of serious infections (e.g., sepsis, pneumonia, and pyelonephritis), or hospitalization or treatment with intravenous antibiotics for infections within 2 months before screening;

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да